Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0EWQKX
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Ozuriftamab vedotin
|
|||||
| Synonyms |
Ba-3021; CAB-ADC; CAB-ROR2; CAB-ROR2-ADC
Click to Show/Hide
|
|||||
| Organization |
BioAtla, Inc.; Kaibos (Shanghai) Biomedical Co., Ltd.
|
|||||
| Drug Status |
Phase 2
|
|||||
| Indication |
In total 5 Indication(s)
Head and neck cancer [ICD11:2B60-2B6E]
Phase 2
Melanoma [ICD11:2C30]
Phase 2
Non-small cell lung cancer [ICD11:2C25]
Phase 2
Ovarian cancer [ICD11:2C73]
Phase 2
Triple negative breast cancer [ICD11:2C60-2C65]
Phase 2
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
Ozuriftamab
|
Antibody Info | ||||
| Antigen Name |
Tyrosine-protein kinase transmembrane receptor ROR2 (ROR2)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
Vedotin
|
|||||
| Puchem SID | ||||||
| Drugbank ID | ||||||
| ChEBI ID | ||||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.